var data={"title":"Chlorpropamide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Chlorpropamide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5888?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=chlorpropamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Chlorpropamide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150611\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Chlorpropamide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150648\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidiabetic Agent, Sulfonylurea</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150615\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, type 2: </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial:</i> 250 mg once daily or in divided doses if GI intolerance occurs; consider conservative doses for malnourished or debilitated patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Titration:</i> After 5 to 7 days of initiation, subsequent daily dosages may be increased or decreased by 50 to 125 mg at 3- to 5-day intervals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance:</i> 100 to 250 mg once daily or in divided doses if GI intolerance occurs; doses &le;100 mg/day may be adequate in some mildly diabetic patients; severely diabetic patients may require 500 mg/day; avoid doses &gt;750 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Central (neurogenic) diabetes insipidus</b>\n      <b> (off-label)</b>\n      <b>:</b> <b>Note:</b> Very limited data: Oral: 125 to 250 mg once or twice daily; higher dosages may produce additional antidiuretic effect but may also be associated with increased hypoglycemia (Cushard 1971; Wales 1971; Webster 1970)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150616\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>Initial:</i> 100 to 125 mg once daily or in divided doses if GI intolerance occurs; after 5 to 7 days of initiation, subsequent daily dosages may be increased or decreased by 50 to 125 mg at 3- to 5-day intervals (slower upward titration may be appropriate in older patients)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150617\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">No specific dosage adjustment provided in manufacturer&rsquo;s labeling; conservative initial and maintenance doses are recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Alternate recommendations (Aronoff, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &gt;50 mL/minute: Reduce dose by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;50 mL/minute: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemodialysis: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous renal replacement therapy (CRRT): Avoid use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150618\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">No specific dosage adjustment provided in manufacturer&rsquo;s labeling; conservative initial and maintenance doses are recommended in patients with liver impairment since chlorpropamide undergoes extensive hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150589\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150574\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9460444\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer once daily with breakfast. Daily dose may be divided to reduce GI upset. Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150592\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, type 2:</b> As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722062\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Central (neurogenic) diabetes insipidus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150653\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">ChlorproPAMIDE may be confused with chlorproMAZINE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Diabinese may be confused with DiaBeta</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Chlorpropamide is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) because of its prolonged half-life in older adults, which may cause prolonged hypoglycemia. In addition, chlorpropamide may cause syndrome of inappropriate antidiuretic hormone secretion (SIADH) (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Chlorpropamide is identified as a high-risk medication in patients 65 years and older on the PQA's Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) Star Rating System for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Diabinese [Multiple international markets] may be confused with Diamox brand name for acetazolamide [Canadan, multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150581\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Disulfiram-like reaction, dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus (&lt;3%), maculopapular rash (&le;1%), urticaria (&le;1%), erythema multiforme, exfoliative dermatitis, skin photosensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hepatic porphyria, hypoglycemia, porphyria cutanea tarda, SIADH (syndrome of inappropriate antidiuretic hormone secretion), weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea (&lt;5%), anorexia (&lt;2%), diarrhea (&lt;2%), hunger (&lt;2%), vomiting (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholestatic jaundice, hepatic failure, hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Proctocolitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150595\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to chlorpropamide or any component of the formulation; type 1 diabetes mellitus; diabetic ketoacidosis (with or without coma)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150578\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS, 1998) have not supported an association.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal or hepatic function; use with caution. Autonomic neuropathy, advanced age, and concomitant use of beta-blockers or other sympatholytic agents may impair the patient&rsquo;s ability to recognize the signs and symptoms of hypoglycemia; use with caution. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfonamide (&ldquo;sulfa&rdquo;) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;  Long half-life: Patients should be properly instructed in the early detection and treatment of hypoglycemia; long half-life may complicate recovery from excess effects. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment.  Additional antidiabetic therapy (eg, insulin) will be required. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150643\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150583\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9253&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbocisteine: Sulfonylureas may enhance the adverse/toxic effect of Carbocisteine. Specifically, sulfonylureas may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May decrease the metabolism of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Sulfonylureas. Management: Seek alternatives when possible.  If used together, monitor closely for increased effects of sulfonylureas if fluconazole is initiated/dose increased, or decreased effects if fluconazole is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving both basal insulin and a sulfonylurea.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May enhance the hypoglycemic effect of Sulfonylureas. Management: Sulfonylurea dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miconazole (Oral): May enhance the hypoglycemic effect of Sulfonylureas. Miconazole (Oral) may increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitiglinide: May enhance the adverse/toxic effect of Sulfonylureas.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RaNITIdine: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Sulfonylureas. Management: Seek alternatives to these combinations when possible.  Monitor closely for diminished therapeutic effects of sulfonylureas if rifampin is initiated/dose increased, or enhanced effects if rifampin is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonamide Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazolidinediones: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinary Acidifying Agents: May increase the serum concentration of ChlorproPAMIDE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150607\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Possible disulfiram-like reaction may occur with concurrent ethanol use. Management: Monitor patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150584\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150598\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Chlorpropamide crosses the placenta and measurable serum concentrations can be found in infants exposed in utero. Severe hypoglycemia lasting 4 to 10 days has been noted in infants born to mothers taking a sulfonylurea (including chlorpropamide) at the time of delivery; additional adverse events have also been reported and may be influenced by maternal glycemic control (Jackson 1962; Kemball 1970; Uhrig 1983; Zucker 1968).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2018c; Blumer 2013). Agents other than chlorpropamide are currently recommended to treat diabetes in pregnant women (ADA 2018c). The manufacturer recommends if chlorpropamide is used during pregnancy, it should be discontinued at least 1 month before the expected delivery date.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5651827\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Chlorpropamide is present in breast milk. Breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150599\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May cause GI upset; take with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150587\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood glucose, HbA<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018a]); monitor for signs and symptoms of hypoglycemia (fatigue, sweating, blurred vision)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150590\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2018a):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary plasma glucose: 80 to 130 mg/dL (more or less stringent goals may be appropriate based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL (more or less stringent goals may be appropriate based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 2018b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary plasma glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150577\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150594\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: 3-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.13-0.23 L/kg (Arrigoni 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic (~80%), primarily via CYP2C9; forms metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~36 hours; prolonged in elderly or with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease: 50-200 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 2-4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (unchanged drug and as hydroxylated or hydrolyzed metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150597\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (ChlorproPAMIDE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $120.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $254.03</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150600\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abemide (JP, TW);</li>\n      <li>Adiaben (HR);</li>\n      <li>Anti-D (SG);</li>\n      <li>Arodoc C (JP);</li>\n      <li>Biodiabes (UY);</li>\n      <li>BPros (KR);</li>\n      <li>Chlormide (JP);</li>\n      <li>Chlorpropamid (PL);</li>\n      <li>Copamide (IN);</li>\n      <li>Dabinese (VE);</li>\n      <li>Diabemide (BF, BJ, CI, ET, GH, GM, GN, IT, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Diabenese (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CO, CR, CY, DO, EG, ET, GB, GH, GM, GN, GR, GT, GY, HN, IL, IQ, IR, IT, JM, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, OM, PA, PR, PT, QA, SC, SD, SL, SN, SR, SV, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Diabezin (TW);</li>\n      <li>Diabines (SE);</li>\n      <li>Diabinese (AR, AU, BE, BR, CH, CL, EC, HK, HR, IE, KR, LU, PE, PH, PK, PL, SA, TH, TR, UY);</li>\n      <li>Diabitex (BB, BM, BS, BZ, GY, JM, NL, SR, TT, ZA);</li>\n      <li>Dibecon (TH);</li>\n      <li>Glicorp (BR);</li>\n      <li>Hypomide (ZA);</li>\n      <li>Insogen (MX);</li>\n      <li>Litangen (TW);</li>\n      <li>Meldian (HR);</li>\n      <li>Mellitos C (JP);</li>\n      <li>Propamide (MY, SG);</li>\n      <li>Trane (AR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins, &quot;Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,&quot; <i>Obstet Gynecol</i>, 2005, 105(3):675-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG)Committee on Practice Bulletins&mdash;Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/29370047/pubmed\" target=\"_blank\" id=\"29370047\">29370047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222377\"></a>American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1):S55-S64. doi: 10.2337/dc18-S006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/29222377/pubmed\" target=\"_blank\" id=\"29222377\">29222377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222382\"></a>American Diabetes Association (ADA). 11. Older adults: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S119-S125. doi: 10.2337/dc18-S011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/29222382/pubmed\" target=\"_blank\" id=\"29222382\">29222382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222384\"></a>American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018c;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). Standards of medical care in diabetes - 2014. <i>Diabetes Care.</i> 2014;37(1):S14-S74.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 111.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arrigoni L, Fundak G, Horn J, et al, &ldquo;Chlorpropamide Pharmacokinetics in Young Healthy Adults and Older Diabetic Patients,&rdquo; <i>Clin Pharm</i>, 1987, 6(2):162-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/3665370/pubmed\" target=\"_blank\" id=\"3665370\">3665370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;A Study of the Effects of Hypoglycemia Agents on Vascular Complications in Patients With Adult-onset Diabetes. VI. Supplementary Report on Nonfatal Events in Patients Treated With Tolbutamide. The University Group Diabetes Program,&rdquo; <i>Diabetes</i>, 1976, 25(12):1129-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/992232/pubmed\" target=\"_blank\" id=\"992232\">992232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/15303450/pubmed\" target=\"_blank\" id=\"15303450\">15303450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"5563815\"></a>Cushard WG Jr, Beauchamp CJ, Martin ND. Oral therapy of diabetes insipidus with chlorpropamide. <i>Calif Med</i>. 1971;115(2):1-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/5563815/pubmed\" target=\"_blank\" id=\"5563815\">5563815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group,&rdquo; <i>Lancet</i>, 1998, 352(9131):854-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/9742977/pubmed\" target=\"_blank\" id=\"9742977\">9742977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jackson WP, Campbell GD, Notelovitz M, et al, &quot;Tolbutamide and Chlorpropamide During Pregnancy in Human Diabetics,&quot; <i>Diabetes</i>, 1962, 11(Suppl):98-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/13964271/pubmed\" target=\"_blank\" id=\"13964271\">13964271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/15644481/pubmed\" target=\"_blank\" id=\"15644481\">15644481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kemball ML, McIver C, Milner RD, et al, &quot;Neonatal Hypoglycaemia in Infants of Diabetic Mothers Given Sulphonylurea Drugs in Pregnancy,&quot; <i>Arch Dis Child</i>, 1970, 45(243):696-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/5477685/pubmed\" target=\"_blank\" id=\"5477685\">5477685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkman M, Briscoe VJ, Clark N, et al, &quot;Diabetes in Older Adults: A Consensus Report,&quot; <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/23106132/pubmed\" target=\"_blank\" id=\"23106132\">23106132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitzmiller JL, Block JM, Brown FM, et al, &quot;Managing Preexisting Diabetes for Pregnancy: Summary of Evidence and Consensus Recommendations for Care,&quot; <i>Diabetes Care</i>, 2008, 31(5):1060-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/18445730/pubmed\" target=\"_blank\" id=\"18445730\">18445730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al, &quot;Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,&quot; <i>Diabetes Care</i>, 2007, 30(Suppl 2):S251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"4809640\"></a>Rad&oacute; JP. Combination of carbamazepine and chlorpropamide in the treatment of &quot;hyporesponder&quot; pituitary diabetes insipidus. <i>J Clin Endocrinol Metab</i>. 1974;38(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/4809640/pubmed\" target=\"_blank\" id=\"4809640\">4809640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/15242722/pubmed\" target=\"_blank\" id=\"15242722\">15242722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/15373844/pubmed\" target=\"_blank\" id=\"15373844\">15373844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uhrig JD and Hurley RM, &quot;Chlorpropamide in Pregnancy and Transient Neonatal Diabetes Insipidus,&quot; <i>Can Med Assoc J</i>, 1983, 128(4):368, 370-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/6821792/pubmed\" target=\"_blank\" id=\"6821792\">6821792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    UK Prospective Diabetes Study (UKPDS) Group, &ldquo;Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33),&rdquo; <i>Lancet</i>, 1998, 352(9131):837-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/9742976/pubmed\" target=\"_blank\" id=\"9742976\">9742976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verbalis JG, &ldquo;Diabetes Insipidus,&rdquo; <i>Rev Endocr Metab Disord</i>, 2003, 4(2):177-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/12766546/pubmed\" target=\"_blank\" id=\"12766546\">12766546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"5171634\"></a>Wales JK, Fraser TR. The clinical use of chlorpropamide in diabetes insipidus. <i>Acta Endocrinol (Copenh)</i>. 1971;68(4):725-736.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/5171634/pubmed\" target=\"_blank\" id=\"5171634\">5171634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"4189879\"></a>Webster B, Bain J. Antidiuretic effect and complications of chlorpropamide therapy in diabetes insipidus. <i>J Clin Endocrinol Metab</i>. 1970;30(2):215-227.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/4189879/pubmed\" target=\"_blank\" id=\"4189879\">4189879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zucker P and Simon G, &quot;Prolonged Symptomatic Neonatal Hypoglycemia Associated With Maternal Chlorpropamide Therapy,&quot;<i> Pediatrics</i>, 1968, 42(5):824-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chlorpropamide-drug-information/abstract-text/5685364/pubmed\" target=\"_blank\" id=\"5685364\">5685364</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9253 Version 160.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F150611\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F150648\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F150615\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F150616\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F150617\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F150618\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F150589\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F150574\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9460444\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F150592\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722062\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F150653\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F150581\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F150595\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F150578\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F150643\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F150583\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F150607\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F150584\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F150598\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5651827\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F150599\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F150587\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F150590\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F150577\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F150594\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F150597\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F150600\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9253|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=chlorpropamide-patient-drug-information\" class=\"drug drug_patient\">Chlorpropamide: Patient drug information</a></li></ul></div></div>","javascript":null}